Tue, Jul 7, 2015
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

Systematic hedge fund group Cantab Capital names Dr Matthew Killeya and Dr Genia Diamond partners

Monday, April 08, 2013

Dr. Ewan Kirk
Opalesque Industry Update - Cantab Capital Partners, the systematic global macro manager has announced that Dr Matthew Killeya (Senior Scientist) and Dr. Genia Diamond (Head of Business Development), have been named partners in the firm.

The announcement is in recognition of Dr. Killeya’s and Dr.Diamond’s contribution to Cantab’s business success and growth. Genia has lead the Investor Relations team that has overseen Cantab’s assets increase fivefold to USD 5,3 billion since 2011.

Matthew’s primary focus is on investment strategy development, having contributed strategies in all three of the clusters within the portfolio (momentum, value and short term).

Commenting on the move, Dr. Ewan Kirk said: “Our investors know that we take both our investment models and investor relations immensely seriously. Both Genia and Matthew have contributed significantly to these respective functions, as well as the overall development of Cantab. As a result we are truly pleased they have accepted our offer to join the partnership.”

Press release

Cantab Capital Partners LLP is a $5.3 billion total assets under management systematic global macro manager based in Cambridge, England. Cantab was founded in 2006 by Dr Ewan Kirk (ex-Goldman Sachs), Erich Schlaikjer (ex-Goldman Sachs) and Chris Pugh (ex-KBC). Dr Tom Howat became a Partner in 2011. The investor base is 60% institutional, 35% fund of funds, and 5% family offices/high net worth individuals. www.cantabcapital.com

Dr Genia Diamond – Head of Business Development
Genia leads the team responsible for all investor-related activities helping to further expand the firm’s reputation and place amongst investors globally.

Genia joined Cantab from OMAM UK and prior to that she was at Solent Capital and BlueCrest Capital. She started her career in asset management as a senior HF researcher at PAAMCO. Genia has a PhD in linguistics from the Moscow State University, an MBA from Erasmus University in the Netherlands and achieved an MA (honours) in Linguistics & Culture Studies from the Moscow State University.

Dr Matthew Killeya – Senior Scientist
Matthew works on all aspects of programme and portfolio construction and has driven developments in these areas, including contributing several new strategies to the portfolio.

More recently Matt’s focus has been on short term execution algorithms and strategies to trade options as a natural diversifier to the futures strategies.

Previously Matt was a senior managing researcher at Winton Capital Management for five years. Matt has a PhD in Bayesian statistics from Durham University. Prior to that, Matt obtained a first class Master of Mathematics degree, also from Durham University.

Bg

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Opalesque Exclusive: New systematic strategy managed alongside research firm outperforms S&P500[more]

    Benedicte Gravrand, Opalesque Geneva for New Managers: An emerging CTA manager explains how he runs his strategy, which is based on an index produced by a research firm. Peter Turk is head of

  2. Opalesque Exclusive: New systematic strategy embraces machine learning[more]

    Benedicte Gravrand, Opalesque Geneva for New Managers: The founder of a New York-based systematic trading firm, which offers a hybrid between alpha strategies and alternative feta at lower fees, describes his approa

  3. Larry Robbins' hedge fund Glenview buys 1m Tenet Healthcare shares[more]

    Komfie Manalo, Opalesque Asia: Glenview Capital Management said it bought an additional 979,482 shares at Tenet Healthcare Corp valued at $53.80 million, raising its stakes in the healthcare services company to 15.16%, reported

  4. Legal - Grayson’s hedge funds under scrutiny for possible ethics violations, Court rejects hedge fund’s motion to block merger of Samsung affiliates[more]

    Grayson’s hedge funds under scrutiny for possible ethics violations From Freebeacon.com: Rep. Alan Grayson is finding himself in hot water over managing hedge funds that bear his name, actions that are in possible violation of House ethics rules. Sitting members of Congress are prohibite

  5. Hedge funds decline in June as stocks tumble on Greek woes[more]

    From Bloomberg.com: Hedge funds posted losses across strategies last month as uncertainty over whether Greece will remain in the euro sent global stock markets tumbling. Winton Capital Management declined about 3.1 percent in June in its $12.1 billion Winton Futures Fund, leaving it down 1.9 percent

 

banner